ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

sapanisertib

Also written as “Sapanisertib”, “MLN0128” and “TAK-128”.

Its studies are mostly in Breast Neoplasms · Endometrial Neoplasms · Diabetic Neuropathies · Carcinoma, Non-Small-Cell Lung · Clear-cell metastatic renal cell carcinoma, led by 3 companies.

Drug pageSapanisertib: every studyAll 47 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Sep 27, 200514 company-led studies, 2 open or runningNext primary completion: Sep 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda80 open or runningphase 2since Sep 27, 2005Sep 27, 2005none ahead
Calithera Biosciencesits history only30 open or runningphase 2since Apr 28, 2016Jul 21, 2014none ahead
Faeth Therapeuticsits history only32 open or runningphase 2since Feb 7, 2022Feb 7, 2022Sep 2028phase 2 · NCT06463028

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Takeda only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 27, 2005First study: phase 2 study in Diabetic NeuropathiesFirst studyNCT00229437 · 343 enrolled · United States, Canada
  2. Sep 17, 2008Phase 2 study in Diabetic NeuropathiesNCT00756041 · 221 enrolled
  3. Jan 27, 2010Phase 1 study in Advanced Solid MalignanciesNCT01058707 · 198 enrolled · United States, Spain
  4. May 5, 2010Phase 1 study in Multiple MyelomaNCT01118689 · 39 enrolled · United States
  5. Feb 21, 2011Phase 1 study in Hematologic NeoplasmsNCT01351350 · 68 enrolled · United States
  6. Jul 10, 2013Phase 1 study in Advanced Nonhematologic MalignanciesNCT01899053 · 101 enrolled · United States, Spain, United Kingdom
  7. Mar 25, 20162 phase 2 studiesNCT02724020, NCT02725268

TargetBeta

MTOR →read by rule
“Serine/threonine-protein kinase mTOR inhibitor”ChEMBL 37, by rule

Other programs on MTOR

ProgramCompanyFurthest phaseStudies
SirolimusPfizerphase 466
gedatolisibrulePfizerphase 39
PI3K/mTOR Kinase Inhibitor WXFL10030390ruleshanghai-jiatan-pharmatech-co-ltdphase 36

Studies

All 8 Takeda leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02725268Endometrial Neoplasms · United States, Australia, Belgium and more2CompletedJul 2, 2019241
NCT02724020Clear-cell metastatic renal cell carcinoma · United States, Canada, Czechia and more2CompletedFeb 3, 202096
NCT01899053Advanced Nonhematologic Malignancies · United States, Spain, United Kingdom1CompletedJan 31, 2017101
NCT01351350Hematologic Neoplasms · United States1CompletedSep 15, 201768
NCT01118689Multiple Myeloma · United States1CompletedMay 201339
NCT01058707Advanced Solid Malignancies · United States, Spain1CompletedFeb 7, 2019198
NCT00756041Diabetic Neuropathies2TerminatedSep 2006221
NCT00229437Diabetic Neuropathies · United States, Canada2CompletedMay 2006343

How it is read

Names in the registry

  • “Sapanisertib”, 5 entries
  • “MLN0128”, 4 entries
  • “TAK-128”, 4 entries
  • “TAK-228”, 2 entries
  • “sapanisertib”, 1 entry

Codes read as this program: TAK128.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.